A
The startup develops targeted therapies for blood cancers using single-cell multi-omic technology to identify curative treatments for myeloproliferative neoplasms. This approach focuses on mutations in cancer stem cells within the bone marrow, enabling precise therapeutic interventions.
Updated 20 months ago
Funding
$8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OS
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops targeted therapies for blood cancers using single-cell multi-omic technology to identify curative treatments for myeloproliferative neoplasms. This approach focuses on mutations in cancer stem cells within the bone marrow, enabling precise therapeutic interventions.